The DOI matches its Crossref record; 85 of the 87 references it cites were found in a registry or an index.
Drug repurposing: a promising tool to accelerate the drug discovery process
Open accessAbstract
Traditional drug discovery and development involves several stages for the discovery of a new drug and to obtain marketing approval. It is necessary to discover new strategies for reducing the drug discovery time frame. Today, drug repurposing has gained importance in identifying new therapeutic uses for already-available drugs. Typically, repurposing can be achieved serendipitously (unintentional fortunate observations) or through systematic approaches. Numerous strategies to discover new indications for FDA-approved drugs are discussed in this article. Drug repurposing has therefore become a productive approach for drug discovery because it provides a novel way to explore old drugs for new use but encounters several challenges. Some examples of different approaches are reviewed here.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These tools can identify ligands, decode drug ingredient binding schemas, and highlight promising candidates from an expansive list of potential compounds.27,31,32”
From Drug repurposing for cancer therapy (2024) · cites this paper as [27]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Chong, C. R., & Sullivan, D. J. (2007) · Nature · doi:10.1038/448645a · Cited by 996
Opportunities and challenges in phenotypic drug discovery: an industry perspective
Moffat, J. G., Vincent, F., Lee, J. A., Eder, J., & Prunotto, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.111 · Cited by 939
Rare cancers are not so rare: The rare cancer burden in Europe
Gatta, G., van der Zwan, J. M., Casali, P. G., Siesling, S., Tos, A. P. D., Kunkler, I. H., Otter, R., Licitra, L. F., Mallone, S., Tavilla, A., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.08.008 · Cited by 813
Systematic integration of biomedical knowledge prioritizes drugs for repurposing
Himmelstein, D. S., Lizee, A., Hessler, C., Brueggeman, L., Chen, S. L., Hadley, D., Green, A., Khankhanian, P., & Baranzini, S. E. (2017) · eLife · doi:10.7554/elife.26726 · Cited by 666
Arrowsmith, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3439 · Cited by 622
Polypharmacology: drug discovery for the future
Reddy, A. S., & Zhang, S. (2012) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.12.74 · Cited by 498
Phase III and submission failures: 2007–2010
Arrowsmith, J. E. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3375 · Cited by 480
Phenotypic screens as a renewed approach for drug discovery
Zheng, W., Thorne, N., & McKew, J. C. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.07.001 · Cited by 438
Jin, G., & Wong, S. T. C. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.005 · Cited by 426
Novel Data-Mining Methodologies for Adverse Drug Event Discovery and Analysis
Harpaz, R., DuMouchel, W., Shah, N. H., Madigan, D., Ryan, P. B., & Friedman, C. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.50 · Cited by 411
Challenges and opportunities of drug repositioning
Novac, N. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.03.004 · Cited by 381
Metformin in cancer prevention and therapy.
Kasznicki, J., Śliwińska, A., & Drzewoski, J. (2014) · PubMed Central · doi:10.3978/j.issn.2305-5839.2014.06.01 · Cited by 362
Jahchan, N. S., Dudley, J. T., Mazur, P. K., Flores, N. M., Yang, D., Palmerton, A., Zmoos, A., Vaka, D., Tran, K. Q. T., Zhou, M. J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0183 · Cited by 358
Dapsone in dermatology and beyond
Wozel, G., & Blasum, C. (2013) · Archives of Dermatological Research · doi:10.1007/s00403-013-1409-7 · Cited by 354
Leigh, M. J. S., Nguyen, D. V., Mu, Y., Winarni, T. I., Schneider, A., Chechi, T., Polussa, J., Doucet, P., Tassone, F., Rivera, S. M., et al. (2013) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e318287cd17 · Cited by 298
In silico repositioning of approved drugs for rare and neglected diseases
Ekins, S., Williams, A. J., Krasowski, M. D., & Freundlich, J. S. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.02.016 · Cited by 294
Hernández, J. J., Pryszlak, M., Smith, L., Yanchus, C., Kurji, N., Shahani, V. M., & Molinski, S. V. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00273 · Cited by 281
Verapamil and beta cell function in adults with recent-onset type 1 diabetes
Ovalle, F., Grimes, T., Xu, G., Patel, A. J., Grayson, T. B., Thielen, L. A., Li, P., & Shalev, A. (2018) · Nature Medicine · doi:10.1038/s41591-018-0089-4 · Cited by 249
Liposomal amphotericin B and leishmaniasis: Dose and response
Sundar, S., & Chakravarty, J. (2010) · Journal of Global Infectious Diseases · doi:10.4103/0974-777x.62886 · Cited by 217
Fosmidomycin, a Novel Chemotherapeutic Agent for Malaria
Lell, B., Ruangweerayut, R., Wiesner, J., Missinou, M. A., Schindler, A., Baranek, T., Hintz, M., Hutchinson, D., Jomaa, H., & Kremsner, P. G. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.2.735-738.2003 · Cited by 217
Drug repositioning: Re-investigating existing drugs for new therapeutic indications
Padhy, B., & Gupta, Y. (2011) · Journal of Postgraduate Medicine · doi:10.4103/0022-3859.81870 · Cited by 206
Fyn kinase inhibition as a novel therapy for Alzheimer’s disease
Nygaard, H. B., van Dyck, C. H., & Strittmatter, S. M. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt238 · Cited by 206
Jacquemet, G., Baghirov, H., Georgiadou, M., Sihto, H., Peuhu, E., Cettour-Janet, P., He, T., Perälä, M., Kronqvist, P., Joensuu, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms13297 · Cited by 186
Repurposing Strategies for Therapeutics
Sleigh, S. H., & Barton, C. L. (2010) · Pharmaceutical Medicine · doi:10.1007/bf03256811 · Cited by 166
Puljak, L., Marin, A., Vrdoljak, D., Markotić, F., Utrobičić, A., & Tugwell, P. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009865.pub2 · Cited by 147
Current Screening Methodologies in Drug Discovery for Selected Human Diseases
Lage, O. M., Ramos, M. C., Calisto, R., Almeida, E., Vasconcelos, V. M., & Vicente, F. (2018) · Marine Drugs · doi:10.3390/md16080279 · Cited by 139
Vaidya, B., Parvathaneni, V., Kulkarni, N. S., Shukla, S. K., Damon, J. K., Sarode, A., Kanabar, D. D., Garcia, J., Mitragotri, S., Muth, A., et al. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.10.181 · Cited by 127
Self-citationCorriden, R., Hollands, A., Olson, J., Derieux, J., Lopez, J. M., Chang, J. T., Gonzalez, D. J., & Nizet, V. (2015) · Nature Communications · doi:10.1038/ncomms9369 · Cited by 116
Effect of Nitroxoline on Angiogenesis and Growth of Human Bladder Cancer
Shim, J. S., Matsui, Y., Bhat, S., Nacev, B. A., Xu, J., Bhang, H.-E. C., Dhara, S., Han, K. C., Chong, C. R., Pomper, M. G., et al. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq457 · Cited by 112
Repurposing itraconazole as an anticancer agent
Tsubamoto, H., Ueda, T., Inoue, K., Sakata, K., Shibahara, H., & Sonoda, T. (2017) · Oncology Letters · doi:10.3892/ol.2017.6325 · Cited by 107
Endocrinology, T. L. D. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30006-3 · Cited by 107
NQO2 Is a Reactive Oxygen Species Generating Off-Target for Acetaminophen
Miettinen, T. P., & Björklund, M. (2014) · Molecular Pharmaceutics · doi:10.1021/mp5004866 · Cited by 91
Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence
Konstantinos, & Hatzimouratidis (2006) · Clinical Interventions in Aging · doi:10.2147/ciia.2006.1.4.403 · Cited by 90
Cruz-Muñiz, M. Y., López-Jácome, L. E., Hernández-Durán, M., Franco‐Cendejas, R., Licona-Limón, P., Ramos-Balderas, J. L., Martínez‐Vázquez, M., Belmont-Díaz, J., Wood, T. K., & García‐Contreras, R. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.08.022 · Cited by 87
Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar)
Wiwanitkit, V. (2012) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s30139 · Cited by 85
Drug Repositioning Approaches for the Discovery of New Therapeutics for Alzheimer's Disease
Kim, T. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0325-7 · Cited by 85
Costabile, G., d’Angelo, I., Rampioni, G., Bondì, R., Pompili, B., Ascenzioni, F., Mitidieri, E., Bianca, R. D. D. V., Sorrentino, R., Miro, A., et al. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00098 · Cited by 84
Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders
Lee, H.-M., & Kim, Y. (2016) · Schizophrenia Research and Treatment · doi:10.1155/2016/6378137 · Cited by 82
Dittmar, A., Drozda, A. A., & Blader, I. J. (2016) · mSphere · doi:10.1128/msphere.00042-15 · Cited by 75
Predicting Targeted Polypharmacology for Drug Repositioning and Multi- Target Drug Discovery
Liu, X., Zhu, F., H., X., Shi, Z., Yang, S., Wei, Y., & Chen, Y. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867311320130005 · Cited by 74
Drug Repurposing and the Medicinal Chemist
Aubé, J. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300114c · Cited by 73
Gene expression‐based drug repurposing to target aging
Dönertaş, H. M., Fuentealba, M., Partridge, L., & Thornton, J. M. (2018) · Aging Cell · doi:10.1111/acel.12819 · Cited by 71
In Vitro Screening for Drug Repositioning
WILKINSON, G. F., & Pritchard, K. (2014) · SLAS DISCOVERY · doi:10.1177/1087057114563024 · Cited by 70
COMPUTATIONAL APPROACHES FOR DRUG REPOSITIONING AND COMBINATION THERAPY DESIGN
Kotelnikova, E. A., Yuryev, A., Mazo, I. A., & Daraselia, N. (2010) · Journal of Bioinformatics and Computational Biology · doi:10.1142/s0219720010004732 · Cited by 69
Target-Based Drug Repositioning Using Large-Scale Chemical–Protein Interactome Data
Sawada, R., Iwata, H., Mizutani, S., & Yamanishi, Y. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00330 · Cited by 69
Tyrosine kinase inhibitor conjugated quantum dots for non-small cell lung cancer (NSCLC) treatment
Kulkarni, N. S., Parvathaneni, V., Shukla, S. K., Barasa, L., Perron, J. C., Yoganathan, S., Muth, A., & Gupta, V. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.03.026 · Cited by 68
Self-citationLin, S.-Y., Chang, H.-H., Lai, Y.-H., Lin, C., Chen, M.-H., Chang, G., Tsai, M.-F., & Chen, J. J. W. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123305 · Cited by 67
Network based elucidation of drug response: from modulators to targets
Iorio, F., Sáez-Rodríguez, J., & di Bernardo, D. (2013) · BMC Systems Biology · doi:10.1186/1752-0509-7-139 · Cited by 67
Exploring potential of quantum dots as dual modality for cancer therapy and diagnosis
Kulkarni, N. S., Guererro, Y., Gupta, N., Muth, A., & Gupta, V. (2018) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2018.12.010 · Cited by 66
Self-citationOvercoming obstacles to repurposing for neurodegenerative disease
Shineman, D. W., Alam, J. J., Anderson, M., Black, S. E., Carman, A. J., Cummings, J. L., Dacks, P. A., Dudley, J. T., Frail, D. E., Green, A. M., et al. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.76 · Cited by 60
Drug repurposing through nonhypothesis driven phenotypic screening
Reaume, A. G. (2011) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2011.09.007 · Cited by 60
DrugSig: A resource for computational drug repositioning utilizing gene expression signatures
Wu, H., Huang, J., Zhong, Y., & Huang, Q. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177743 · Cited by 60
Repurposing drugs to fast-track therapeutic agents for the treatment of cryptococcosis
Truong, M., Monahan, L. G., Carter, D. A., & Charles, I. G. (2018) · PeerJ · doi:10.7717/peerj.4761 · Cited by 57
Alshareef, A., Zhang, H.-F., Huang, Y.-H., Wu, C., Zhang, J. D., Wang, P., El‐Sehemy, A., Fares, M., & Lai, R. L. (2016) · Scientific Reports · doi:10.1038/srep33710 · Cited by 56
BCL3 expression promotes resistance to alkylating chemotherapy in gliomas
Wu, L., Bernal, G. M., Cahill, K. E., Pytel, P., Fitzpatrick, C. A., Mashek, H., Weichselbaum, R. R., & Yamini, B. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar2238 · Cited by 56
Murteira, S., Millier, A., Ghezaiel, Z., & Lamure, M. P. (2014) · Journal of Market Access & Health Policy · doi:10.3402/jmahp.v2.22813 · Cited by 55
Sporn, M. B., Dowsett, S. A., Mershon, J. L., & Bryant, H. U. (2004) · Clinical Therapeutics · doi:10.1016/s0149-2918(04)90127-0 · Cited by 55
Cheminformatic/bioinformatic analysis of large corporate databases: Application to drug repurposing
Loging, W., Rodriguez‐Esteban, R., Hill, J., Freeman, T. C., & Miglietta, J. J. (2011) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2011.06.004 · Cited by 50
Hafeez, B. B., Ganju, A., Sikander, M., Kashyap, V. K., Hafeez, Z. B., Chauhan, N., Malik, S., Massey, A. E., Tripathi, M. K., Halaweish, F. T., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0157 · Cited by 49
Pathway-Based Drug Repositioning for Breast Cancer Molecular Subtypes
Mejía-Pedroza, R. A., Enríquez, J. E., & Lemus, E. H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00905 · Cited by 49
Repurposing Toremifene for Treatment of Oral Bacterial Infections
Gerits, E., Defraine, V., Vandamme, K., Cremer, K. D., Brucker, K. D., Thevissen, K., Cammue, B. P. A., Beullens, S., Fauvart, M., Verstraeten, N., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01846-16 · Cited by 47
Zilbermintz, L., Leonardi, W., Jeong, S., Sjodt, M., McComb, R. C., Ho, C.-L. C., Retterer, C. J., Gharaibeh, D. N., Zamani, R., Soloveva, V., et al. (2015) · Scientific Reports · doi:10.1038/srep13476 · Cited by 45
Self-citationPantziarka, P., Pirmohamed, M., & Mirza, N. (2018) · BMJ · doi:10.1136/bmj.k2701 · Cited by 45
Deotarse, P. P., Jain, A. S., Baile, M. B., Kolhe, N. S., & Kulkarni, A. (2015) · International journal of pharma research and review · Cited by 44
Cells, E., Mazzanti, C. M., Lorang, D., Lorang, D., Roberts, D., Bevilacqua, G., & Bevilacqua, G. (2004) · Genome Research · doi:10.1101/gr.2552804 · Cited by 44
Prediction of new drug indications based on clinical data and network modularity
Yu, L., Ma, X., Zhang, L., Zhang, J., & Gao, L. (2016) · Scientific Reports · doi:10.1038/srep32530 · Cited by 43
Genetic and Rare Diseases Information Center (GARD)
Hoskins, A. (2022) · Medical Reference Services Quarterly · doi:10.1080/02763869.2022.2131143 · Cited by 43
Systematic integration of biomedical knowledge prioritizes drugs for repurposingPreprint
Himmelstein, D. S., Lizée, A., Hessler, C., et al. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/087619 · Cited by 40
The evolution of drug discovery: from phenotypes to targets, and back
Al‐Ali, H. (2016) · MedChemComm · doi:10.1039/c6md00129g · Cited by 39
Prevention of colorectal cancer using COX-2 inhibitors: basic science and clinical applications
Arthur, J. C. (2004) · Frontiers in bioscience · doi:10.2741/1429 · Cited by 36
Editorial: Drug Repositioning: Current Advances and Future Perspectives
Nishimura, Y., & Hara, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01068 · Cited by 32
Advantages and Challenges in Drug Re-Profiling
Agrawal, P. (2015) · Journal of Pharmacovigilance · doi:10.4172/2329-6887.s2-e002 · Cited by 31
Galvin, B. D., Li, Z., Villemaine, E., Poole, C. B., Chapman, M., Pollastri, M. P., Wyatt, P. G., & Carlow, C. K. S. (2014) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0003145 · Cited by 28
The current management of brain metastasis in melanoma: a focus on riluzole
Yu, L. J., Wall, B., & Chen, S. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1055321 · Cited by 22
Issa, N. T., Peters, O. J., Byers, S. W., & Dakshanamurthy, S. (2015) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207318666150803130138 · Cited by 22
Recent successes and future predictions on drug repurposing for rare diseases
Bloom, B. E. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2016.1120664 · Cited by 22
In vivo phenotypic screening: clinical proof of concept for a drug repositioning approach
Ciallella, J. R., & Reaume, A. G. (2017) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2017.04.001 · Cited by 21
Zador, Z. E., King, A. T., & Geifman, N. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194701 · Cited by 21
Kim, K. J., Yang, H. Y., Chang, S., Kim, Y., Lee, K. M., Lee, B., & Kim, H. S. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3759 · Cited by 14
Drug repositioning and indication discovery using description logics
Croset, S. (2014) · Apollo (University of Cambridge) · doi:10.17863/cam.15985 · Cited by 8
Data Mining Open Source Databases for Drug Repositioning using Graph Based Techniques
McGarry, K., & Daniel, U. (2014) · Cited by 7
A New Market Access Path for Repurposed DrugsPreprint
Pahud, D., Mitchell, L., WILBANKS, J. T., Stevens, M., Weir, S. J., McBride, J., Portilla, L., Pezalla, E., Nameth, M., O’Donoghue, B., et al. (2014) · SSRN Electronic Journal · doi:10.2139/ssrn.2437502 · Cited by 4
Experimental diabetes drug shows promise in Parkinson’s disease
(2016) · Pharmaceutical journal/The pharmaceutical journal · doi:10.1211/pj.2016.20202062 · Cited by 1
Flagged first, then by citations
2 of the 87 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Repurposing drugs helps patients with rare diseases. Available at: https://www.elsevier.com/connect/repurposing-drugs-helps-patients-with-rare-diseases.
- Sekhon, 2013, Repositioning drugs and biologics: retargeting old/existing drugs for potential new therapeutic applications, J. Pharm. Educ. Res., 4, 1
Cited by
Sorted by citations
Artificial intelligence in cancer target identification and drug discovery
You, Y., Lai, X., Pan, Y. F., Zheng, H., Vera, J., Liu, S., Deng, S., & Zhang, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00994-0 · Cited by 499
“It refers to a method that identi fi es new indications for approved drugs or drug candidates which have failed in the development phase 232 .”
MethodDrug repurposing for cancer therapy
Xia, Y., Sun, M., Huang, H., & Jin, W.-L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01808-1 · Cited by 443
“27,28 More often, these techniques are synergistically utilized.”
BackgroundMethodDrug Repurposing: An Effective Tool in Modern Drug Discovery
Kulkarni, V. S., Alagarsamy, V., Solomon, V. R., Jose, P. A., & Murugesan, S. (2023) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162023020139 · Cited by 264
Pillaiyar, T., Meenakshisundaram, S., Manickam, M., & Sankaranarayanan, M. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112275 · Cited by 140
“This means the success rate of drug approval is so high when compared to the traditional methods [202].”
ResultUtilizing drug repurposing against COVID-19 – Efficacy, limitations, and challenges
Parvathaneni, V., & Gupta, V. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118275 · Cited by 138
“Apart from serendipitous observations, drug repurposing can be executed through several strategies including binding assays and phenotypic screening methods or computational methods, as presented in Table 1 [23].”
InfluentialSelf-citation
Metadata
- Authors
- Parvathaneni, V., Kulkarni, N. S., Muth, A., & Gupta, V.
- Affiliations
- St. John's University (US)
- Corresponding author
- Gupta, Vivek
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 24
- Issue
- 10
- Pages
- 2076-2085
- ISSN
- 1359-6446 (ISSN-L)
- PMC
- PMC11920972
- OpenAlex
- W2951512731
- Semantic Scholar
- 023e169dfa4fe591ef24cf91b93e0d7371bb3400
- Cited by
- 597
- References
- 87
- Citations by year
- 2026: 80 · 2025: 137 · 2024: 130 · 2023: 96 · 2022: 77 · 2021: 52 · 2020: 22 · 2019: 3
- FWCI
- 3.18
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Drug Discovery Today (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Figshare (submittedVersion, cc-by)
- Health Research Alliance (cc-by)
- Funders
- NIH (1R15HL138606-01A1)
- American Heart Association (18AIREA33960072)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Pharmacology (medical) › Historical Medical Research and Treatments
- Keywords
- drug repurposing, FDA-approved drugs, new therapeutic indications, serendipitous drug discovery, drug development challenges
- MeSH terms
- Humans, Drug Discovery, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
